Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSKP.L Regulatory News (SKP)

  • There is currently no data for SKP

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) - Vectura Group PLC

9 Jun 2016 12:00

RNS Number : 7254A
Peel Hunt LLP
09 June 2016
 

 FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Peel Hunt LLP

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Vectura Group PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

Vectura Group PLC

(d) Date dealing undertaken:

8 June 2016

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

 

Yes

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

Ordinary Shares

Buy

173,599

160.10 GBX

158.10 GBX

Ordinary Shares

Sell

177,506

160.30 GBX

158.10 GBX

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

9 June 2016

Contact name:

Paul Crispin

Telephone number:

0207 418 8988

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERFLMPTMBTMMBF
Date   Source Headline
28th Jan 20167:00 amRNSMundipharma appointed as partner for flutiform
21st Jan 201610:36 amRNSHolding(s) in Company
11th Jan 20167:00 amRNSPre-Close Update
6th Jan 201610:40 amRNSDirector/PDMR Shareholding
23rd Dec 20157:00 amRNSSKP-2076 to be partnered with Mundipharma
21st Dec 20152:47 pmRNSDirector Declaration
15th Dec 20153:36 pmRNSFavourable Resolution with FDA Relating to EXPAREL
14th Dec 201510:47 amRNSHolding(s) in Company
3rd Dec 201510:02 amRNSDirector/PDMR Shareholding
1st Dec 20155:26 pmRNSDirectorate Change
1st Dec 201510:01 amRNSHolding(s) in Company
27th Nov 20153:55 pmRNSHolding(s) in Company
26th Nov 20157:00 amRNSTrading Update and Capital Markets Meeting
18th Nov 20159:00 amRNSPresents at Jefferies Global Healthcare Conference
4th Nov 201510:52 amRNSDirector/PDMR Shareholding
5th Oct 20159:40 amRNSDirector/PDMR Shareholding
4th Sep 20159:24 amRNSDirector/PDMR Shareholding
1st Sep 201510:29 amRNSHolding(s) in Company
26th Aug 20157:00 amRNS2015 Interim Results
6th Aug 20157:00 amRNSNotice of Results
4th Aug 20153:36 pmRNSDirector/PDMR Shareholding
30th Jul 20152:11 pmRNSHolding(s) in Company
3rd Jul 201510:03 amRNSDirector/PDMR Shareholding
25th Jun 20157:00 amRNSInterim Results Pre-close Trading Update
2nd Jun 20153:03 pmRNSDirector/PDMR Shareholding
1st Jun 20159:00 amRNSPresenting at Jefferies 2015 Healthcare Conference
12th May 20154:26 pmRNSResult of AGM
12th May 20157:00 amRNSAGM Trading Update
11th May 201510:08 amRNSDirector/PDMR Shareholding
24th Apr 201510:27 amRNSDirector Declaration
10th Apr 20154:33 pmRNSAnnual Financial Report
2nd Apr 201512:17 pmRNSDirector/PDMR Shareholding
26th Mar 20154:59 pmRNSDirector/PDMR Shareholding
26th Mar 20154:34 pmRNSDirector/PDMR Shareholding
24th Mar 20157:00 amRNSFinal Results
20th Mar 20159:00 amRNSSkyepharma wins at PLC Awards
11th Mar 20159:49 amRNSHolding(s) in Company
4th Mar 201510:45 amRNSNotice of Results
3rd Mar 20152:58 pmRNSDirector/PDMR Shareholding
25th Feb 20154:14 pmRNSHolding(s) in Company
13th Feb 20157:00 amRNSEarly repayment of the CRC Finance facility
9th Feb 20154:26 pmRNSHolding(s) in Company
3rd Feb 20152:25 pmRNSDirector/PDMR Shareholding
28th Jan 20154:46 pmRNSHolding(s) in Company
14th Jan 20153:46 pmRNSHolding(s) in Company
12th Jan 20157:00 amRNSPre-close update
5th Jan 20155:38 pmRNSDirector/PDMR Shareholding
8th Dec 20142:13 pmRNSDirector/PDMR Shareholding
2nd Dec 20144:33 pmRNSDirector/PDMR Shareholding
1st Dec 20147:04 amRNSKyorin launches flutiform 120-puff version

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.